ClinicalTrials.gg
CompletedNCT02926898Updated Nov 2, 2022Results posted

A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome

A Phase 3 interventional study of ZX008 (Fenfluramine Hydrochloride) and Matching Placebo in Dravet Syndrome, sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.. Completed at 28 sites in 7 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing fenfluramine in Epilepsies, Myoclonic — 2 open to participants now, 2 under way, none of them phase 3. Fenfluramine · Epilepsies, Myoclonic.

Enrollment
4th of 11
87 · median 25
Started
2017
with 1 other
Phase 3
7 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
5 of 11
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Among the 11 studies testing fenfluramine in Epilepsies, Myoclonic, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 3rd registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

2 of the 11 studies testing fenfluramine in Epilepsies, Myoclonic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fenfluramine

Fenfluramine: first FDA approval 2020 (FINTEPLA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing fenfluramine in Epilepsies, Myoclonic, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of ZX008 (fenfluramine hydrochloride) when added to adjunctive antiepileptic stiripentol treatment in children and young adults with Dravet syndrome.

Read the detailed description

This is a multicenter, 2-cohort trial to first assess the pharmacokinetic and safety profile of a single dose of ZX008 (fenfluramine hydrochloride) oral solution when added to a standard Dravet syndrome treatment regimen containing valproate (VPA) and clobazam (CLB), with or without stiripentol (STP) (Cohort 1), followed by a randomized, double-blind, placebo-controlled parallel group evaluation of the efficacy, safety, and tolerability of ZX008 as adjunctive therapy for seizures in children and young adults with Dravet syndrome (Cohort 2).

03

Conditions studied

  • Dravet Syndrome

Keywords

  • Seizure
  • Tonic clonic
  • Epilepsy
  • Myoclonic
  • Encephalopathy
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subject must be male or non-pregnant, non-lactating female, aged 2 to 18 years (inclusive).
  • Subject must have documented medical history to support a clinical diagnosis of Dravet syndrome, where convulsive seizures are not completely controlled by current antiepileptic drugs.
  • Subject must be receiving a therapeutically relevant and stable dose of stiripentol (STP) plus clobazam (CLB) and/or valproate (VPA), and for at least 4 weeks prior to screening and be expected to remain stable throughout the study (Cohort 2 only).
  • Subject must be receiving a stable dose of CLB and VPA, administered twice daily (BID), to be eligible for Dose Regimen 1 and 2, or subject must be receiving a stable dose of CLB, VPA, and STP, administered BID, to be eligible for Dose Regimen 3 (Cohort 1 only).

Key Exclusion Criteria:

  • Subject has a known to fenfluramine or any of the in the study medication.
  • Subject has pulmonary arterial hypertension.
  • Subject has a current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction, or stroke.
  • Subject has a current or recent history of anorexia nervosa, bulimia, or depression within the prior year that required medical treatment or psychological treatment for a duration greater than 1 month.
  • Subject has a current or past history of glaucoma.
  • Subject is receiving concomitant therapy with: centrally acting anorectic agents; monoamine-oxidase inhibitors; any centrally acting compound with clinically appreciable amount of serotonin agonist or antagonist properties, including serotonin reuptake inhibition; triptans, atomoxetine, or other centrally acting noradrenergic agonists; cyproheptadine, and/or cytochrome P450 (CYP) 2D6/3A4/2B6 inhibitors/substrates.
  • Subject is currently taking carbamazepine ,oxcarbazepine, eslicarbazepine, phenobarbital, or phenytoin, or has taken any of these within the past 30 days, as maintenance therapy.
  • Subject has a positive result on urine tetrahydrocannabinol (THC) panel or whole blood cannabidiol (CBD) at the Screening Visit.
  • Subject has a condition, or has had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to the Screening Visit, other than epilepsy, that would negatively impact study participation, collection of study data, or pose a risk to the subject.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Cohort 2: ZX008 0.5 mg/kg/day

    ZX008 0.5 mg/kg/day (maximum 20 mg/day) dose supplied as an oral solution administered twice a day (BID) in equally divided doses with food.

    Drug: ZX008 (Fenfluramine Hydrochloride)

  • Placebo comparator
    Cohort 2: Matching Placebo

    Matching placebo administered twice a day (BID) in equally divided doses with food.

    Drug: Matching Placebo

Interventions

  • ZX008 0.5 mg/kg/day (maximum 20 mg/day). ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. \*Note: The 0.5 mg/kg/day dose of ZX008 fenfluramine hydrochloride in this study is equivalent to 0.4 mg/kg/day (maximum 17 mg/day) dose of fenfluramine base.

  • DrugMatching Placebo

    Matching Placebo

06

What researchers measure

Primary outcomes

  1. Change in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) Period

    Monthly (28 day) convulsive seizure frequency (CSF) was based on electronic diary data obtained for each participant. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). The number of convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day CSF.

    Time frame: 15 weeks (combined Titration + Maintenance Period)

Secondary outcomes

  1. Percentage of Participants Who Achieved ≥ a 50% Reduction in Convulsive Seizure Frequency From Baseline to the Combined Titration + Maintenance Period

    Percentage of participants who achieved ≥ a 50% reduction in convulsive seizure frequency from Baseline compared to the combined Titration + Maintenance Periods in the ZX008 0.5 mg/kg/day vs placebo groups.

    Time frame: 15 weeks (combined Titration + Maintenance Period)

  2. Longest Convulsive Seizure-Free Interval (Days)

    Comparison of the duration of the longest convulsive seizure-free interval (days) during the combined Titration + Maintenance Periods for the ZX008 0.5 mg/kg/day and placebo groups.

    Time frame: 15 weeks (combined Titration + Maintenance Period)

07

Results

Posted Oct 19, 2022

Participant flow

A total of 28 study sites in Canada, France, Germany, the Netherlands, Spain, the United Kingdom, and the United States enrolled participants for Study 1504 Cohort 2.

Participant flow — Overall Study
MilestoneCohort 2: ZX008 0.5 mg/kg/DayCohort 2: Matching Placebo
Started4344
Completed3641
Not completed73

Outcome measures

PrimaryChange in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) Period

Monthly (28 day) convulsive seizure frequency (CSF) was based on electronic diary data obtained for each participant. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). The number of convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day CSF.

Time frame:
15 weeks (combined Titration + Maintenance Period)
Reported as:
Mean · Convulsive seizures per 28 days
Change in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) Period
Convulsive seizures per 28 daysCohort 2: ZX008 0.5 mg/kg/DayCohort 2: Matching Placebo
Change in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) Period-3.18 ± 44.121-0.65 ± 8.767
Statistical analysis
  • Cohort 2: ZX008 0.5 mg/kg/Day vs Cohort 2: Matching Placebo · ANCOVA · p = <0.001 (Analysis of covariance (ANCOVA) model with treatment group (ZX008 or placebo) and age group (\< 6 years, ≥ 6 years) as factors, and with log baseline frequency as a covariate, and log CSF as the outcome variable.) · Percent difference: -54.0 · 95% CI -67.2 to -35.6
SecondaryPercentage of Participants Who Achieved ≥ a 50% Reduction in Convulsive Seizure Frequency From Baseline to the Combined Titration + Maintenance Period

Percentage of participants who achieved ≥ a 50% reduction in convulsive seizure frequency from Baseline compared to the combined Titration + Maintenance Periods in the ZX008 0.5 mg/kg/day vs placebo groups.

Time frame:
15 weeks (combined Titration + Maintenance Period)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved ≥ a 50% Reduction in Convulsive Seizure Frequency From Baseline to the Combined Titration + Maintenance Period
Percentage of participantsCohort 2: ZX008 0.5 mg/kg/DayCohort 2: Matching Placebo
Percentage of Participants Who Achieved ≥ a 50% Reduction in Convulsive Seizure Frequency From Baseline to the Combined Titration + Maintenance Period53.54.5
Statistical analysis
  • Cohort 2: ZX008 0.5 mg/kg/Day vs Cohort 2: Matching Placebo · Regression, Logistic · p = <0.001A logistic regression model using a categorical response variable as a function of Treatment group, Baseline seizure frequency, and age group.
SecondaryLongest Convulsive Seizure-Free Interval (Days)

Comparison of the duration of the longest convulsive seizure-free interval (days) during the combined Titration + Maintenance Periods for the ZX008 0.5 mg/kg/day and placebo groups.

Time frame:
15 weeks (combined Titration + Maintenance Period)
Reported as:
Median · Days
Longest Convulsive Seizure-Free Interval (Days)
DaysCohort 2: ZX008 0.5 mg/kg/DayCohort 2: Matching Placebo
Longest Convulsive Seizure-Free Interval (Days)22.0 (3.0 to 105.0)13.0 (1.0 to 40.0)
Statistical analysis
  • Cohort 2: ZX008 0.5 mg/kg/Day vs Cohort 2: Matching Placebo · Wilcoxon (Mann-Whitney) · p = 0.004

Adverse events

Collected over The period of observation for Adverse Events extended from the time the subject gave informed consent until the end of the Follow-up Visit (up to Day 120 [Visit 13]).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 2: ZX008 0.5 mg/kg/Day0/43 (0%)6/43 (14%)42/43 (97.7%)
Cohort 2: Matching Placebo0/44 (0%)7/44 (15.9%)42/44 (95.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventCohort 2: ZX008 0.5 mg/kg/DayCohort 2: Matching Placebo
SeizureNervous system disorders1/434/44
Status epilepticusNervous system disorders3/430/44
OsteochondritisMusculoskeletal and connective tissue disorders1/430/44
LethargyNervous system disorders1/430/44
Abdominal painGastrointestinal disorders0/431/44
PyrexiaGeneral disorders0/431/44
Gastroenteritis viralInfections and infestations0/431/44
Lower respiratory tract infectionInfections and infestations0/431/44
PneumoniaInfections and infestations0/431/44
Generalised tonic-clonic seizureNervous system disorders0/431/44
Most frequent other events
Showing 10 of 26
Most frequent other events
EventCohort 2: ZX008 0.5 mg/kg/DayCohort 2: Matching Placebo
Decreased appetiteMetabolism and nutrition disorders19/435/44
NasopharyngitisInfections and infestations7/4315/44
FatigueGeneral disorders11/432/44
PyrexiaGeneral disorders11/434/44
DiarrheaGastrointestinal disorders10/433/44
SeizureNervous system disorders2/437/44
Blood glucose decreasedInvestigations6/432/44
LethargyNervous system disorders6/432/44
BronchitisInfections and infestations5/432/44
Status epilepticusNervous system disorders5/430/44

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 2: ZX008 0.5 mg/kg/DayCohort 2: Matching PlaceboTotal
Cohort 28.8 ± 4.569.4 ± 5.059.1 ± 4.80
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 2: ZX008 0.5 mg/kg/DayCohort 2: Matching PlaceboTotal
Cohort 2 — Female201737
Cohort 2 — Male232750
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 2: ZX008 0.5 mg/kg/DayCohort 2: Matching PlaceboTotal
Hispanic or Latino3710
Not Hispanic or Latino252247
Unknown or Not Reported151530
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 2: ZX008 0.5 mg/kg/DayCohort 2: Matching PlaceboTotal
Cohort 2 — American Indian or Alaska Native000
Cohort 2 — Asian213
Cohort 2 — Native Hawaiian or Other Pacific Islander000
Cohort 2 — Black or African American123
Cohort 2 — White232952
Cohort 2 — More than one race000
Cohort 2 — Unknown or Not Reported171229
Region of Enrollment
Region of Enrollment(Participants)Cohort 2: ZX008 0.5 mg/kg/DayCohort 2: Matching PlaceboTotal
Netherlands8210
France131023
Canada437
United States111122
Germany033
Spain4610
United Kingdom3912
08

Study locations

28 sites
  • University of California San Francisco
    San Francisco, California 94158, United States
  • Children'S Hospital Colorado
    Aurora, Colorado 80045, United States
  • Ann & Robert H. Lurie Children'S Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Children'S Hospital of Michigan
    Detroit, Michigan 48201, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Bc Children'S Hospital Division of Neurology
    Vancouver, British Columbia V6H 3V4, Canada
  • Chu Sainte-Justine Hospital Neurology Clinic
    Montréal, Quebec H3T 1C5, Canada
  • Chu Amiens Picardie Service de Neurologie Pédiatrique
    Amiens, 80480, France
  • Chu de Bordeaux Hôpital Des Enfants
    Bordeaux, 33076, France
  • HÔPITAL FEMME-MÈRE-ENFANT Hôpital Service de Neurologie Pédiatrique
    Bron, 69677, France
  • Chru de Lille Hôpital Roger Salengro
    Lille, 59037, France
  • Hôpital de La Timone, Service de Neuro-Métabolisme Pédiatrique
    Marseille, 13385, France
  • Hôpital Necker-Enfants Malades
    Paris, 75015, France
  • Hôpital Robert-Debré
    Paris, 75019, France
  • Chu de Toulouse - Hôpital Des Enfants
    Toulouse, 31059, France
  • Hôpital D'Enfants Chur de Nancy
    Vandœuvre-lès-Nancy, 54511, France
  • Krankenhaus Mara, Epilepsie-Zentrum Bethel
    Bielefeld, 33617, Germany
  • Universitätsklinikum Schleswig-Holstein, Klinik Für Neuropädiatrie
    Kiel, 24105, Germany
  • Kleinwachau Sächsisches Epilepsiezentrum Radeberg
    Radeberg, 01454, Germany
  • Epilepsiecentrum Kempenhaeghe
    Heeze, 5591 VE, Netherlands
  • Stichting Epilepsie Instellingen Nederland
    Zwolle, 8025 BV, Netherlands
  • Hospital Sant Joan de Déu Barcelona
    Barcelona, 08950, Spain
  • Hospital Ruber Internacional-Servicio de Neurología
    Madrid, 28034, Spain
  • Cliníca Universidad de Navarra Nidad de Neuropediatría
    Pamplona, 31008, Spain
  • Royal Hospital For Children, Queen Elizabeth University, Institute of Neurosciences Hospital
    Glasgow, Scotland G51 4TF, United Kingdom
  • Alder Hey Children'S Nhs Foundation Trust, Littlewood'S Neurosciences Unit
    Liverpool, L12 2AP, United Kingdom
  • Evelina London Children'S Hospital, Paediatric Neurosciences
    London, SE1 7EH, United Kingdom
  • Great Ormond Street Hospital For Children Nhs Foundation Trust
    London, WC1N 3JH, United Kingdom
09

References and documents

Publications

  • Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, Stephani U, Laux L, Wirrell E, Knupp K, Chiron C, Farfel G, Galer BS, Morrison G, Lock M, Agarwal A, Auvin S; FAiRE, DS Study Group. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial. JAMA Neurol. 2020 Mar 1;77(3):300-308. doi: 10.1001/jamaneurol.2019.4113. PubMed 31790543 ↗
  • Cross JH, Galer BS, Gil-Nagel A, Devinsky O, Ceulemans B, Lagae L, Schoonjans AS, Donner E, Wirrell E, Kothare S, Agarwal A, Lock M, Gammaitoni AR. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 2021 Dec;93:154-159. doi: 10.1016/j.seizure.2021.10.024. Epub 2021 Nov 2. PubMed 34768178 ↗
  • Sullivan J, Perry MS, Wheless JW, Galer B, Gammaitoni A. Fenfluramine responder analyses and numbers needed to treat: Translating epilepsy trial data into clinical practice. Eur J Paediatr Neurol. 2021 Mar;31:10-14. doi: 10.1016/j.ejpn.2021.01.005. Epub 2021 Jan 22. PubMed 33540241 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jun 2018, 16 months.

Results were first posted in Oct 2022, 4 years 4 months after primary completion.

Of 15 phase 3 interventional studies under Epilepsies, Myoclonic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 72. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2016
First posted
Oct 6, 2016
StartActual
Jan 27, 2017
Primary completionActual
Jun 5, 2018
CompletionActual
Jun 5, 2018
Results first posted
Oct 19, 2022
Last update
Nov 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02926898
Responsible party
Sponsor
First posted
Oct 6, 2016
Start date
Jan 27, 2017
Primary completion
Jun 5, 2018
Completion
Jun 5, 2018
Results posted
Oct 19, 2022
Last update
Nov 2, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenfluramine

Start the discussion